Hints and tips:
Related Special Reports
...Uğur Şahin, the company’s chief executive, will update on ten oncology trials in the year ahead at a pharmaceutical industry conference in San Francisco later on Tuesday....
...Uğur Şahin, BioNTech’s chief executive, said the company had recently added antibody drug conjugates, one of a newly popular drug class that aims to be more targeted than chemotherapy....
...He is currently the face of a new Versace Icons collection, picked by Donatella Versace and shot for the campaign by Mert & Marcus. Murphy enjoys clothes and fashion....
...It’s almost too much when Mert Günal, our perma-smiling, multitalented lead guide, squats on a granite block in the desolate agora and plays a haunting, timeless tune on his ney, a bamboo flute with a 5,000...
...Uğur Şahin, BioNTech’s chief executive, immediately offered her a role as vice-president of research....
...“The path to personalisation requires really an understanding and an interaction with the regulators because it’s a new concept,” said Şahin....
...triggers regular soul-searching about what some Germans see as failure of integration, even as figures such as agriculture minister Cem Özdemir and BioNTech founders and Covid-19 vaccine pioneers Uğur Şahin...
...Ugur Sahin, chief executive and co-founder of BioNTech, said the company had allowed people to access a vaccine adapted to the BA.4/BA.5 variants at “unprecedented speed”....
...Uğur Şahin, BioNTech’s chief executive, said the German pharma group had been focused on using “computational solutions” to create personalised drugs that harnessed the power of the immune system, known...
...BioNTech’s chief executive Uğur Şahin said the company was expanding its Covid product pipeline, aiming for “prolonged and broad protection”....
...Dropping his helmet in his office and donning a white coat, Şahin heads to the lab....
...Research and development scientist Deniz Mert Bayram, 25, wears Officine Generale virgin wool Charlene jacket, €450, and matching trousers, €260....
...BioNTech and Pfizer will start a clinical trial of a Covid-19 vaccine adapted to the BA.4 and BA.5 variants of Omicron this month, as the German biotech forecasts an increase in demand at the end of the...
...The session is led by Mert, the resort “fitness guy”, a man with more mosquito bites on his legs than I’ve ever seen concentrated in one place....
...Esad Sahin has lived in Germany for 10 years but is still not a German citizen. The reason: a strict ban on dual nationality that would have obliged him to surrender his Turkish passport....
...“Time is ticking,” said Şahin....
...Sahin has not made any significant share sales....
...Hill is sceptical, however, of Şahin’s focus on tackling cancer with mRNA vaccines. “What we know about treating cancer with vaccines, you wouldn’t start with RNA.”...
...BioNTech chief executive Uğur Şahin said in June it would be “useful” to adapt vaccines “without the requirement to do extra clinical trials” so that jabs could target the latest strains before the virus...
...Chief executive Ugur Sahin said the group had reported “encouraging data” on its first in-human trial of a CAR-T therapy, which engineers T-cells to tackle solid tumours....
...Get the latest worldwide picture with our vaccine tracker Some good news Uğur Şahin and Özlem Türeci, the team behind the pioneering BioNTech Covid-19 jab, told the BBC that vaccines to treat cancer would...
...Uğur Şahin, BioNTech chief executive, last week called on regulators to decide by the end of June whether to approve Covid vaccines targeting the most recent virus strains without first requiring clinical...
...Ugur Sahin, BioNTech’s chief executive, said the study suggested that the lower dose “provides young children with a high level of protection against the recent Covid-19 strains”....
...Sahin is referring to a period before the first world war when Germany had a dominant role in global drug development and manufacturing....
...Sahin rejected patent-sharing as a risk to quality control. Pfizer chief executive Albert Bourla has argued it would disincentivise innovation....
International Edition